Published online Nov 30, 2008.
https://doi.org/10.4111/kju.2008.49.11.974
Epidermal Growth Factor Receptor as Predicting Factor on Biochemical Recurrence after Radical Prostatectomy: A Prospective Study
Abstract
Purpose
We investigated epidermal growth factor receptor (EGFR) expression in prostate cancer (PCa) and their potential role as predicting factor on biochemical recurrence (BCR).
Materials and Methods
Between February 2005 and February 2007, EGFR expression were prospectively evaluated in a consecutive series of 88 PCa patients with the following characteristics: 66 patients treated with retropubic radical prostatectomy (RRP); 22 patients treated with neoadjuvant hormonal therapy followed by RRP. The relationship between EGFR expression and several clinicopathologic parameters were evaluated. The probability of BCR-free survival was determined using the Kaplan-Meier method.
Results
EGFR expression, was evaluated by immunohistochemistry, was found in 31 of 88 (35.2%) patients. 8 of 31 EGFR-positive patients (25.8%) had BCR, whereas only 5 of 57 EGFR-negative patients (8.8%) had BCR (p=0.031) during a median follow-up of 21 months. Among several variables, high serum prostate-specific antigen values (≥20), extraprostatic extension, seminal vesicle invasion, and EGFR expression were the significant predictors of BCR on univariate analysis. But, multivariate analysis showed that no variable was significant predictor of BCR. EGFR-negative patients had a significantly longer mean BCR-free survival time than EGFR-positive patients (p=0.027).
Conclusions
EGFR expression could be an potential predicting factor on BCR following RRP.
Fig. 1
H&E and immunohistochemical evaluation of epidermal growth factor receptor (EGFR) expression in prostate cancer. (A) EGFR-positive tumor (blackish stained) (×200), (B) EGFR-negative tumor (×200).
Fig. 2
Kaplan-Meier method estimates of likelihood of remaining free of biochemical recurrence as related to epidermal growth factor receptor expression (log rank, p=0.027). BCR: biochemical recurrence, EGFR: epidermal growth factor receptor.
Table 1
Patient characteristics
Table 2
Correlation between immunohistochemistry staining for EGFR and clinicopathologic factors
Table 3
Univariate and multivariate analysis of prognostic factors for biochemical recurrence
References
-
Hong JH, Lee HM, Choi HY. The predictors of biochemical recurrence and metastasis following radical perineal prostatectomy in clinically localized prostate cancer. Korean J Urol 2005;46:1161–1167.
-
-
Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002;8:3438–3444.
-
-
Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control 2007;14:295–304.
-
-
Merlino GT. Epidermal growth factor receptor regulation and function. Semin Cancer Biol 1990;1:277–284.
-
-
Haeder M, Rotsch M, Bepler G, Henning C, Havemann K, Heimann B, et al. Epidermal growth factor receptor expression in human lung cancer cell lines. Cancer Res 1988;48:1132–1136.
-
-
Greenberg SD, Fraire AE, Kinner BM, Johnson EH. Tumor cell type versus staging in the prognosis of carcinoma of the lung. Pathol Annu 1987;22:387–405.
-
-
Newby JC, Johnston SR, Smith IE, Dowsett M. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 1997;3:1643–1651.
-
-
Fischer-Colbrie J, Witt A, Heinzl H, Speiser P, Czerwenka K, Sevelda P, et al. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res 1997;17:613–619.
-
-
Mckenzie SJ. Diagnostic utility of oncogenes and their products in human cancer. Biochem Biophys Acta 1991;1072:193–214.
-
-
Hiramatsu M, Kashimata M, Minami N, Sato A, Murayama M, Minami N. Androgenic regulation of epidermal growth factor in the mouse ventral prostate. Biochem Int 1998;17:311–317.
-
-
Fowler JE Jr, Lau JL, Ghosh L, Mills SE, Mounzer A. Epidermal growth factor and prostatic carcinoma: an immunohistochemical study. J Urol 1988;139:857–861.
-
-
Scher HI, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, et al. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res 1995;1:545–550.
-
-
Miller K, Raabe N, Trachtenberg J, Trump D, Wilding G, Das-Gupta A. ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is well tolerated in combination with mitoxantrone and prednisone in patients with hormone-refractory prostate cancer (HRPC). Ann Oncol 2002;13 Suppl 5:91.abstract 327.
-
-
Soulie P, Trump D, Wilding G, Small E, Das-Gupta A. ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with docetaxel and estramustine in patients with hormone-refractory prostate cancer (HRPC). Ann Oncol 2002;13 Suppl 5:91.abstract 328.
-